EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent manner.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG.
Nguyen LL, et al. Among authors: guntupalli sr.
Mol Cancer Res. 2024 Aug 13. doi: 10.1158/1541-7786.MCR-24-0067. Online ahead of print.
Mol Cancer Res. 2024.
PMID: 39136655